John Gerecitano

Publications

• Heat Shock Protein 90 Inhibitors in the Treatment of Cancer: Current Status and Future Directions
  Expert Opinion on Investigational Drugs. May, 2014  |   Pubmed ID: 24669860
• A Phase 1/pharmacokinetic Study of Sunitinib in Combination with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-positive Patients with Cancer: AIDS Malignancy Consortium Trial AMC 061
  Cancer. Apr, 2014  |   Pubmed ID: 24474568
• Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Feb, 2013  |   Pubmed ID: 23248254
• A Phase I Trial of the Kinesin Spindle Protein (Eg5) Inhibitor AZD4877 in Patients with Solid and Lymphoid Malignancies
  Investigational New Drugs. Apr, 2013  |   Pubmed ID: 22615058
• The Impact of Non-drug-related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2012  |   Pubmed ID: 22825582
• Tissue Microarray Analysis Reveals Protein Expression Patterns and Potential Biomarkers of Clinical Benefit to Bortezomib in Relapsed/refractory Non-Hodgkin Lymphoma
  British Journal of Haematology. Jul, 2012  |   Pubmed ID: 22533368
• Augmenting Advance Care Planning in Poor Prognosis Cancer with a Video Decision Aid: a Preintervention-postintervention Study
  Cancer. Sep, 2012  |   Pubmed ID: 22252775
• Normalization of Pre-ASCT, FDG-PET Imaging with Second-line, Non-cross-resistant, Chemotherapy Programs Improves Event-free Survival in Patients with Hodgkin Lymphoma
  Blood. Feb, 2012  |   Pubmed ID: 22184409
• Phase I Trial of Weekly and Twice-weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non-Hodgkin Lymphoma
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2011  |   Pubmed ID: 21346146
• Navitoclax, a Targeted High-affinity Inhibitor of BCL-2, in Lymphoid Malignancies: a Phase 1 Dose-escalation Study of Safety, Pharmacokinetics, Pharmacodynamics, and Antitumour Activity
  The Lancet. Oncology. Dec, 2010  |   Pubmed ID: 21094089
• Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib is Longer Compared with Other Histologic Subtypes
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jan, 2010  |   Pubmed ID: 20068103
• Eine Phase 1 Dosis-Eskalations-Studie Der Sicherheit Und Der Pharmakokinetik Von Roman Proteasom-Inhibitor-Carfilzomib (PR-171) Bei Patienten Mit Hämatologischen Malignitäten
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2009  |   Pubmed ID: 19903785
• The Future of Small Molecule Inhibitors in Lymphoma
  Current Oncology Reports. Sep, 2009  |   Pubmed ID: 19679013
• Phase 2 Study of Weekly Bortezomib in Mantle Cell and Follicular Lymphoma
  British Journal of Haematology. Sep, 2009  |   Pubmed ID: 19624539
• Drug-induced Cutaneous Vasculitis in Patients with Non-Hodgkin Lymphoma Treated with the Novel Proteasome Inhibitor Bortezomib: a Possible Surrogate Marker of Response?
  British Journal of Haematology. Aug, 2006  |   Pubmed ID: 16882131
• Novel Small Molecules in the Treatment of Lymphomas
  Cancer Treatment and Research. 2006  |   Pubmed ID: 16704178
• Treatment of Burkitt Lymphoma in Adults
  Expert Review of Anticancer Therapy. Mar, 2006  |   Pubmed ID: 16503854
• Homocysteine and Prothrombin Fragment 1+2 Levels in Patients with Veno-occlusive Disease After Stem Cell Transplantation
  Journal of Hematotherapy & Stem Cell Research. Apr, 2003  |   Pubmed ID: 12804180